Results 251 to 260 of about 594,568 (282)
Some of the next articles are maybe not open access.
Humanization of Camelid Single-Domain Antibodies
2022Humanization of therapeutic antibodies derived from animal immunizations is often required to minimize immunogenicity risks in humans, which can cause potentially harmful and serious side effects and reduce antibody efficacy. Humanization is typically applied to conventional monoclonal antibodies derived in rodents as well as single-domain antibodies ...
openaire +2 more sources
Improving the targeting of therapeutics with single-domain antibodies
Expert Opinion on Drug Delivery, 2016The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting
Kendrick B Turner +2 more
exaly +3 more sources
Engineering pH-Sensitive Single-Domain Antibodies
2022There is increasing interest in expanding an antibody beyond high affinity and specificity. One such feature is custom regulation of the binding event, such as pH-dependent control. Here, we provide a methodology for generating single-domain antibodies (sdAbs) that bind their antigen in a pH-dependent fashion.
Tosha M, Laughlin, James R, Horn
openaire +2 more sources
Single-Domain Antibodies for Intracellular Toxin Neutralization
2022Ricin is a plant-derived toxin with a history as a biothreat agent. The toxin's enzymatic subunit, ricin toxin A chain (RTA), is a ribosome-inactivating protein that, when delivered into the cytoplasm of mammalian cells, arrests protein synthesis with extraordinary efficiency.
Timothy F, Czajka, Nicholas J, Mantis
openaire +2 more sources
Engineered antibody fragments and the rise of single domains
Nature Biotechnology, 2005With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals. In fact, by 2008, engineered antibodies are predicted to account for >30% of all revenues in the biotechnology market. Smaller recombinant antibody fragments (for example,
Philipp, Holliger, Peter J, Hudson
openaire +2 more sources
Expression of Single-Domain Antibodies in Bacterial Systems
2012In this chapter we describe in detail the current protocols that are used to express single-domain antibodies in bacteria. Bacteria are among the most common expression systems for expressing recombinant proteins. We present different approaches for carrying out periplasmic and cytoplasmic expression, as well as small-scale and large-scale expression ...
Baral, T.N., Arbabi-Ghahroudi, M.
openaire +3 more sources
Application of Single-Domain Antibodies in Tumor Histochemistry
2012High avidity, pentameric, single-domain antibodies, oligomerized through the B subunit of verotoxin, are excellent immunohistochemical reagents. The resulting molecules are termed pentabodies. Here, we describe the immunostaining of tissue sections with ES1, a pentabody recognizing CEACAM6 which is overexpressed in several cancers.
Maik, K.T., MacKenzie, C.R.
openaire +2 more sources
Prospective Applications of Single-Domain Antibodies in Biomedicine
Molecular Biology, 2020Methods that utilize highly specific antibodies, anti-idiotypic antibodies, various recombinant molecules with antibody properties and immunocorrection and immunoprophylaxis with the help of vaccines are in demand and are intensely developed in the field of biomedicine.
openaire +2 more sources
Expression of single-domain antibody in different systems
Applied Microbiology and Biotechnology, 2017Camelid single-domain antibodies (sdAbs, VHHs, or Nanobodies®) are types of antibody fragments that are composed of the heavy-chain variable domain only. These VHHs possess unique structural and functional features, as they are small in size and exhibit thermal stability and high solubility. Compared to conventional antibodies, VHHs can be manufactured
Yongkang, Liu, He, Huang
openaire +2 more sources
Bispecific Single Domain Antibodies
2011Monoclonal antibodies are now widely recognized as therapeutic molecules and more than 25 molecules have been approved in the United States and other countries. Despite these successes, the clinical activity of these molecules is still far from optimal and new solutions have to be found, especially in the field of cancer therapy.
Patrick Chames, Daniel Baty
openaire +1 more source